Trial Profile
A study investigating survival rates after treatment with S-1 (Gimeracil/oteracil/tegafur) given postoperatively in patients with curatively resected non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2015
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.